HIV — SCE Infectious Diseases MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Tenofovir DF/Emtricitabine plus Dolutegravir for 28 days
BHIVA/BASHH 2021 PEP guidelines recommend a 28-day course of Tenofovir DF/Emtricitabine plus a third agent. Dolutegravir has replaced Raltegravir as the preferred third agent due to once-daily dosing and improved tolerability. PEP should be initiated as soon as possible, ideally within 1 hour and no later than 72 hours post-exposure. This is a significant exposure (hollow-bore needle, high source viral load) warranting PEP.
Reference: BHIVA/BASHH 2021 – Guidelines on the use of HIV post-exposure prophylaxis; UKHSA 2022 – PEP guidance